EyePoint, Inc. - Common Stock - fluxo de caixa (NASDAQ:EYPT)

Financials

Fluxo de caixa operacional -14.44 M-50.1 M-65 M1.88 M-126.23 M-240.11 M -267.54 M Fluxo de caixa de investimento -362 K-33.12 M-17.27 M-3.31 M-219.35 M68.58 M 88.11 M Fluxo de caixa de financiamento 37.49 M216.9 M-690 K187.07 M164.02 M173.65 M 171.98 M Fluxo de caixa livre -14.44 M-50.1 M-65 M1.88 M-126.23 M-243.39 M -271.54 M

EyePoint, Inc. - Common Stock

EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery. pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner. In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.

EYPT

Financials

EyePoint, Inc. - Common Stock

Notícias

Ensaio clínico para AMD úmida da EyePoint prossegue após revisão de segurança

EyePoint: DURAVYU's Durability Could Drive Significant Upside (NASDAQ:EYPT)

Guggenheim reitera compra em EyePoint e cita avanço em ensaios clínicos

EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates

Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?

EyePoint Pharmaceuticals avança com DURAVYU em conferência da RBC

Guggenheim mantém classificação das ações da EyePoint com base em dados de segurança do Duravyu

Guggenheim reiterates EyePoint stock rating on Duravyu safety data

Mizuho mantém classificação Outperform para ações da EyePoint

EyePoint stock rating maintained at Outperform by Mizuho

H.C. Wainwright eleva preço-alvo das ações da EyePoint para US$ 30

H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress